| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc5f35131e93737075393018b62c34e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_588a9f6f9644c092450c1efd7bf33375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5b5e797569deb1a4a73779563d008eb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-463 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2020-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1621760e22dba9c861a3b64307b9da6e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d26d7709514a8d95c8d2e9ba4b220039 |
| publicationDate |
2022-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4045074-A1 |
| titleOfInvention |
Use of esculentin and its derivatives for use in the treatment of cystic fibrosis |
| abstract |
Are disclosed pharmaceutical compositions comprising as active ingredients Esculentin-1a(1-21)NH 2 and/or Esculentin diastereomer Esc(1-21)-1c for use for restoring dysregulation of water and/or ions content and/or composition of the periciliary liquid due to mutations of the CFTR gene encoding for Cystic fibrosis transmembrane conductance regulator (CFTR) and for use for the treatment of cystic fibrosis. |
| priorityDate |
2019-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |